Addition of melphalan to fludarabine/busulfan (FLU/BU4/MEL) provides survival benefit for patients with myeloid malignancy following allogeneic bone-marrow transplantation/peripheral blood stem-cell transplantation.
In conclusion, FLU/BU4/MEL showed curative potential, even in patients with advanced myeloid malignancies, accompanied by achievement of rapid complete chimerism after allo-BMT/PBSCT. PMID: 30448938 [PubMed - as supplied by publisher] (Source: International Journal of Hematology)
Source: International Journal of Hematology - November 17, 2018 Category: Hematology Authors: Ueda T, Maeda T, Kusakabe S, Fujita J, Fukushima K, Yokota T, Shibayama H, Tomiyama Y, Kanakura Y Tags: Int J Hematol Source Type: research

A high titer of acquired factor V inhibitor in a hemodialysis patient who developed arterial thrombosis.
Abstract An 87-year-old man with diabetes mellitus was admitted to control recurrent bleeding from hemodialysis puncture sites. He was a smoker and had been diagnosed with arteriosclerosis obliterans. His PT and APTT were markedly prolonged, and all coagulation factors were markedly decreased (factor V [FV] activity 
Source: International Journal of Hematology - November 16, 2018 Category: Hematology Authors: Ogawa H, Souri M, Kanouchi K, Osaki T, Ohkubo R, Kawanishi T, Wakai S, Morikane K, Ichinose A Tags: Int J Hematol Source Type: research

Risk factors and timing of autologous stem cell transplantation for patients with peripheral T-cell lymphoma.
Abstract High-dose chemotherapy with autologous stem cell transplantation (HDC-ASCT) is an option for patients with peripheral T-cell lymphoma (PTCL); however, neither prospective nor retrospective studies support proceeding with ASCT upfront, and the timing of HDC-ASCT remains controversial. We retrospectively analyzed the risk factors for outcomes of 570 patients with PTCL, including PTCL not otherwise specified (PTCL-NOS) and angioimmunoblastic T-cell lymphoma (AITL), who received ASCT for frontline consolidation (n = 98 and 75, respectively) or alternative therapies after either relapse (n&thinsp...
Source: International Journal of Hematology - November 14, 2018 Category: Hematology Authors: Yamasaki S, Chihara D, Kim SW, Kawata T, Mizuta S, Ago H, Chou T, Yamane T, Uchiyama H, Oyake T, Miura K, Saito B, Taji H, Nakamae H, Miyamoto T, Fukuda T, Kanda J, Atsuta Y, Suzuki R Tags: Int J Hematol Source Type: research

Characteristics and prognosis of patients with non-immunoglobulin-M monoclonal gammopathy of undetermined significance: a retrospective study.
Abstract Non-immunoglobulin (Ig)-M monoclonal gammopathy of undetermined significance (MGUS) is a precursor lesion with the potential to evolve into a malignant plasma cell neoplasm. The prevalence of MGUS differs by ethnicity and is lower in the Japanese population than in the Western population. However, there is limited evidence about the clinical course of MGUS in Asian races. The present study aims at elucidating the clinical course and prognosis of Japanese patients with non-IgM MGUS in the clinical setting. We retrospectively examined 1009 patients with non-IgM MGUS identified by screening procedures. The m...
Source: International Journal of Hematology - November 8, 2018 Category: Hematology Authors: Kuwabara C, Sakuma Y, Kume A, Tamura Y, Shimizu R, Iwai R, Ishii A, Tanaka H Tags: Int J Hematol Source Type: research

Correction to: Systematic review of pre-clinical chronic myeloid leukaemia.
Abstract The author would like to correct the error in the publication of the original article. The corrected detail is given below for your reading. PMID: 30406326 [PubMed - as supplied by publisher] (Source: International Journal of Hematology)
Source: International Journal of Hematology - November 7, 2018 Category: Hematology Authors: Kuan JW, Su AT, Leong CF, Osato M, Sashida G Tags: Int J Hematol Source Type: research

Correction to: A phase II study of lenalidomide consolidation and maintenance therapy after autologous PBSCT in patients with multiple myeloma.
Abstract In the original publication of this article, "Conflict of interest" was published incorrectly. The corrected "Conflict of interest" is given below for your reading. PMID: 30406327 [PubMed - as supplied by publisher] (Source: International Journal of Hematology)
Source: International Journal of Hematology - November 7, 2018 Category: Hematology Authors: Fuchida SI, Sunami K, Matsumoto M, Okumura H, Murayama T, Miyamoto T, Otsuka E, Fujishima N, Izumi T, Tamaki S, Hiramatsu Y, Kuroda Y, Shimazaki C, Akashi K, Harada M, Japan Study Group for Cell Therapy and Transplantation (JSCT) Tags: Int J Hematol Source Type: research

Presacral extramedullary hematopoiesis under treatment with an erythropoietin-stimulating agent for myelodysplasia.
Abstract PMID: 30386961 [PubMed - as supplied by publisher] (Source: International Journal of Hematology)
Source: International Journal of Hematology - November 1, 2018 Category: Hematology Authors: Konishi T, Doki N, Takaki Y, Igarashi A, Ohashi K Tags: Int J Hematol Source Type: research

Epstein-Barr virus-related diffuse large B-cell lymphoma in mogamulizumab-treated adult T-cell leukemia with incomplete T-cell reconstitution.
Abstract Adult T-cell leukemia (ATL) is an aggressive mature T-cell malignancy with a poor prognosis. The anti-C-C motif chemokine receptor 4 (CCR4) antibody mogamulizumab (moga) reduces ATL cells and induces reconstitution of polyclonal T cells; however, ATL cases often remain resistant and moga sometimes causes fatal immunopathology. Epstein-Barr virus (EBV)-related B-cell lymphoma develops in severely immunocompromised subjects, and is particularly associated with impaired T-cell immunity. Here, we report an ATL patient who had received conventional chemotherapy plus moga, and subsequently developed EBV-related...
Source: International Journal of Hematology - October 27, 2018 Category: Hematology Authors: Kamachi K, Shindo T, Miyahara M, Kitaura K, Akashi M, Shin-I T, Suzuki R, Oshima K, Kimura S Tags: Int J Hematol Source Type: research

A case of recurrent histiocytic sarcoma with MAP2K1 pathogenic variant treated with the MEK inhibitor trametinib.
Abstract Histiocytic sarcoma in advanced clinical stages is typically an aggressive neoplasm, with poor response to conventional chemotherapy. An 18-year-old male with refractory histiocytic sarcoma that had transformed from Rosai-Dorfman disease was admitted to our hospital. A pathogenic variant of MAP2K1 was detected by next-generation sequencing of tumor specimens. Affected regions showed excellent responses to the MEK inhibitor trametinib. It has been reported that RAS/MEK/ERK pathway is activated in many cases of histiocytic sarcoma. MEK inhibition may represent a useful treatment option in histiocytic sarcom...
Source: International Journal of Hematology - October 25, 2018 Category: Hematology Authors: Kumamoto T, Aoki Y, Sonoda T, Yamanishi M, Arakawa A, Sugiyama M, Shirakawa N, Ishimaru S, Saito Y, Maeshima A, Maeda M, Ogawa C Tags: Int J Hematol Source Type: research

Impact of splicing factor mutations on clinical features in patients with myelodysplastic syndromes.
Abstract Splicing factor gene mutations are found in 60-70% of patients with myelodysplastic syndromes (MDS). We investigated the effects of splicing factor gene mutations on the diagnosis, patient characteristics, and prognosis of MDS. A total of 106 patients with MDS were included. The percentage of patients with MDS with ring sideroblasts (14.15%) as per the 2017 WHO classification was significantly higher than that of patients with refractory anemia with ring sideroblasts (2.88%) as per the 2008 WHO classification (P = 0.005). Splicing factor mutations were detected in 32 patients (13 SF3B1, 8 U2...
Source: International Journal of Hematology - October 23, 2018 Category: Hematology Authors: Shingai N, Harada Y, Iizuka H, Ogata Y, Doki N, Ohashi K, Hagihara M, Komatsu N, Harada H Tags: Int J Hematol Source Type: research

Molecular pathogenesis of leukemia and leukemic stem cells (LSCs).
Abstract PMID: 30353275 [PubMed - as supplied by publisher] (Source: International Journal of Hematology)
Source: International Journal of Hematology - October 23, 2018 Category: Hematology Authors: Kizaki M Tags: Int J Hematol Source Type: research

Emicizumab, a humanized bispecific antibody to coagulation factors IXa and X with a factor VIIIa-cofactor activity.
Abstract Hemophilia A is a congenital disorder caused by deficiency or malfunction of coagulation factor (F) VIII. While exogenously provided FVIII effectively reduces bleeding complications in many hemophilia A patients, multiple efforts are underway to develop new drugs to meet the needs that conventional FVIII agents do not. We have been long engaged in creating and clinically developing a humanized anti-FIXa/FX asymmetric bispecific IgG antibody with a FVIIIa-cofactor activity. Since this project was born from a creative and unique idea, our group recognized from the first that it would face many difficulties ...
Source: International Journal of Hematology - October 22, 2018 Category: Hematology Authors: Kitazawa T, Shima M Tags: Int J Hematol Source Type: research

Late-stage myeloma invades kidney without significant effect on renal function: findings from 53 autopsies in a single institute.
Abstract Renal manifestations of multiple myeloma (MM) including cast nephropathy, amyloidosis, and renal calcification have been widely recognized. However, the severity of histopathological findings has not been addressed so far, and the clinical significance of these pathological findings is unclear. We sought to clarify the relationship between the severity of renal pathology and clinical characteristics. We analyzed 53 autopsies performed on patients who died from MM. The kidneys were evaluated using light microscopy, and the severity of pathological findings was recorded. The most common renal lesion was cas...
Source: International Journal of Hematology - October 16, 2018 Category: Hematology Authors: Takano J, Mine S, Mochizuki M, Tanaka N, Hagiwara S Tags: Int J Hematol Source Type: research

Brief history of the Asiatic International Society of Hematology: our roots of international cooperation with Asian countries.
Abstract This year, 2018, marks the 60th anniversary of the Asiatic International Society of Hematology founded in 1958 and it seems to be a fitting occasion on which to reflect on our roots of the international cooperation with Asian countries. The Japanese Society of Hematology held the first meeting of the Asiatic International Society of Hematology in 1958 in Nagoya. Hematologists representing at least 10 Asian countries or districts, including Australia, Burma, Ceylon, Hong Kong, India, Indonesia, Korea, Philippines, Taiwan, and Thailand, participated. This meeting was perhaps the first International Congress...
Source: International Journal of Hematology - October 12, 2018 Category: Hematology Authors: Saito H, Hotta T, Naoe T Tags: Int J Hematol Source Type: research

Immunoparesis in symptomatic multiple myeloma at diagnosis affects PFS with bortezomib-containing induction therapy, but not ASCT consolidation.
Abstract In novel agent era, the impact of immunoparesis at diagnosis on outcomes in symptomatic multiple myeloma (MM) remains unclear. We reviewed medical records of 147 MM patients at Beijing Chao Yang hospital. Most patients exhibited immunoparesis at diagnosis (84%). After a median follow-up of 27 months (range 1-78 months), in the group with immunoparesis at diagnosis, there was a very significantly shorter progression-free survival (PFS) than in the group without immunoparesis (estimated PFS of not reached vs 25 months, P = 0.001). Patients with suppressed Immunoglobulins (Igs) had the tendency...
Source: International Journal of Hematology - October 11, 2018 Category: Hematology Authors: Gao W, Li J, Jian Y, Yang G, Wu Y, Li Y, Len Y, Liu A, Tian Y, Wang H, Zhou H, Zhang Z, Chen W Tags: Int J Hematol Source Type: research

Intracytoplasmic azurophilic inclusions in prolymphocytes.
PMID: 30302738 [PubMed - as supplied by publisher] (Source: International Journal of Hematology)
Source: International Journal of Hematology - October 9, 2018 Category: Hematology Authors: Mackrides N, Lossos IS, Vega F Tags: Int J Hematol Source Type: research

Risk factors and survival impact of readmission after single-unit cord blood transplantation for adults.
Abstract Hospital readmissions have been used as a prognostic indicator for patients receiving allogeneic hematopoietic cell transplantation (HCT). However, the impact of readmission during early and mid-phase of cord blood transplantation (CBT) on long-term outcomes has not been fully investigated. We retrospectively analyzed 156 adult patients who received single-unit CBT in our institute. Among this cohort, thirteen patients (8%) were readmitted within 30 days after discharge, and 27 (17%) were readmitted within 90 days after discharge. The most common causes for readmission within 30 and 90 days of discharge w...
Source: International Journal of Hematology - October 9, 2018 Category: Hematology Authors: Yamagishi Y, Konuma T, Miwa Y, Oiwa-Monna M, Tanoue S, Isobe M, Jimbo K, Mizusawa M, Narita H, Kobayashi K, Kato S, Takahashi S, Tojo A Tags: Int J Hematol Source Type: research

Anti-tissue factor pathway inhibitor (TFPI) therapy: a novel approach to the treatment of haemophilia.
Abstract Novel approaches to the treatment of haemophilia are needed due to the limitations of the current standard of care, factor replacement therapy. Aspirations include lessening the treatment burden and effectively preventing joint damage. Treating haemophilia by restoring thrombin generation may be an effective approach. A promising target for restoring thrombin generation is tissue factor pathway inhibitor (TFPI), a multivalent Kunitz-type serine protease inhibitor that regulates tissue factor-induced coagulation via factor Xa-dependent feedback inhibition of the tissue factor-factor VIIa complex. Inhibitio...
Source: International Journal of Hematology - October 9, 2018 Category: Hematology Authors: Chowdary P Tags: Int J Hematol Source Type: research

Massive bone marrow necrosis revealing an HIV-related primary bone marrow lymphoma: a diagnostic challenge.
We describe the concomitant presence of a primary bone marrow lymphoma (diffuse large B-cell lymphoma-DLBCL), along with an extensive BMN in an HIV patient for the first time in a living individual. HIV infection, BMN and DLBCL presented a multifactorial crossword of molecular events underlying the complex pathophysiology. The exact precipitating pathophysiological events resulting in BMN remain obscure and provide their clear impact for future research. The present report is instructive and also contains a critical review of the literature related to the case presented. PMID: 30293217 [PubMed - as supplied by publish...
Source: International Journal of Hematology - October 6, 2018 Category: Hematology Authors: Diamantidis MD, Gogou V, Koletsa T, Metallidis S, Papaioannou M Tags: Int J Hematol Source Type: research

Cytomegalovirus meningitis in a patient with relapsed acute myeloid leukemia.
Abstract Cytomegalovirus meningitis/meningoencephalitis is a potentially fatal complication following hematopoietic stem cell transplantation that causes significant morbidity and mortality. In the pre-transplant setting, a few cases involving lymphoid malignancies have been reported. However, there have been no reports of patients with myeloid malignancies. A 36-year-old man with relapsed acute myeloid leukemia received high-dose cytarabine-containing salvage chemotherapies and then developed grade 4 lymphopenia for more than one month. Subsequently, the patient developed pyrexia, accompanying headache, nausea, a...
Source: International Journal of Hematology - October 5, 2018 Category: Hematology Authors: Harada K, Sekiya N, Ikegawa S, Sasaki S, Kobayashi T, Ohashi K Tags: Int J Hematol Source Type: research

Venous thromboembolism in relapsed or refractory multiple myeloma patients treated with lenalidomide plus dexamethasone.
In conclusion, VTE occurred in 5-8% of RRMM patients treated with LD over 2 years, and early-onset VTE was a strong indicator of poor prognosis. PMID: 30291558 [PubMed - as supplied by publisher] (Source: International Journal of Hematology)
Source: International Journal of Hematology - October 5, 2018 Category: Hematology Authors: Shin J, Lee JJ, Kim K, Min CK, Lee JO, Suh C, Kim JS, Lee YJ, Yoon SS, Jo JC, Lee HS, Bang SM, Korean Multiple Myeloma 151 Investigators Tags: Int J Hematol Source Type: research

A phase II study of lenalidomide consolidation and maintenance therapy after autologous PBSCT in patients with multiple myeloma.
Abstract The efficacy and safety of lenalidomide (LEN) consolidation therapy and subsequent LEN maintenance therapy after high-dose therapy with autologous peripheral blood stem cell transplantation (auto-PBSCT) were evaluated in patients with newly diagnosed symptomatic multiple myeloma (MM). Forty-one patients were enrolled and received high-dose dexamethasone (DEX) therapy as an initial induction. The patients who did not respond to the DEX therapy were further treated with four cycles of bortezomib plus DEX (BD) induction therapy. For patients who responded to BD, PBSC harvesting was scheduled following high-d...
Source: International Journal of Hematology - October 4, 2018 Category: Hematology Authors: Fuchida SI, Sunami K, Matsumoto M, Okumura H, Murayama T, Miyamoto T, Otsuka E, Fujishima N, Izumi T, Tamaki S, Hiramatsu Y, Kuroda Y, Shimazaki C, Akashi K, Harada M, Japan Study Group for Cell Therapy and Transplantation (JSCT) Tags: Int J Hematol Source Type: research

What do the lineage tracing studies tell us? Consideration for hematopoietic stem cell origin, dynamics, and leukemia-initiating cells.
Abstract The recent advance of technologies enables us to trace the cell fate in vivo by marking the cells that express the gene of interest or by barcoding them at a single cell level. Various tamoxifen-inducible Cre-recombinase mice combined with Rosa-floxed lines are utilized. In this review, with the results revealed by lineage tracing assays, we re-visit the long-standing debate for the origin of hematopoietic stem cells in the mouse embryo, and introduce the view of native hematopoiesis, and possible leukemic-initiating cells emerged during fetal stages. PMID: 30264284 [PubMed - as supplied by publisher...
Source: International Journal of Hematology - September 27, 2018 Category: Hematology Authors: Azevedo Portilho N, Kobayashi M, Yoshimoto M Tags: Int J Hematol Source Type: research

Risk of secondary primary malignancies in multiple myeloma patients with or without autologous stem cell transplantation.
Abstract Outcomes for patients with multiple myeloma (MM) have improved through use of novel treatments, especially lenalidomide combined with autologous stem cell transplantation. However, because of their increased life expectancy, an increased risk of secondary primary malignancies (SPMs) has been observed in MM patients, particularly after lenalidomide maintenance in both transplant-eligible (TE) and transplant-ineligible (TI) patients. To evaluate the incidence and risk factors of developing SPMs, we identified 17 TE-MM and 12 TI-MM patients with SPMs among 211 TE-MM and 280 TI-MM patients, including seven TE...
Source: International Journal of Hematology - September 24, 2018 Category: Hematology Authors: Yamasaki S, Yoshimoto G, Kohno K, Henzan H, Aoki T, Tanimoto K, Sugio Y, Muta T, Kamimura T, Ohno Y, Ogawa R, Eto T, Nagafuji K, Miyamoto T, Akashi K, Iwasaki H, Fukuoka Blood and Marrow Transplantation Group Tags: Int J Hematol Source Type: research

Conspicuous activated lymphocytic proliferation associated with cytokine-release syndrome after CAR T-cell therapy.
PMID: 30238197 [PubMed - as supplied by publisher] (Source: International Journal of Hematology)
Source: International Journal of Hematology - September 20, 2018 Category: Hematology Authors: Wolters R, Curry CV Tags: Int J Hematol Source Type: research

Long-term outcomes in patients treated in the intensive care unit after hematopoietic stem cell transplantation.
Abstract The number of patients who are successfully discharged from the intensive care unit (ICU) after hematopoietic stem cell transplantation (HSCT) remains limited. Most previous studies have evaluated short-term outcomes using ICU mortality; there have been comparatively fewer reports of long-term outcomes. We retrospectively analyzed 39 HSCT patients admitted to the ICU for the first time between April 2008 and July 2014. Performance status was evaluated in four long-term survivors in July 2016. Median age at ICU admission was 54 years (range 30-68). In total, 33 patients (70.2%) required mechanical ven...
Source: International Journal of Hematology - September 20, 2018 Category: Hematology Authors: Nakamura M, Fujii N, Shimizu K, Ikegawa S, Seike K, Inomata T, Sando Y, Fujii K, Nishimori H, Matsuoka KI, Morimatsu H, Maeda Y Tags: Int J Hematol Source Type: research

Deregulated iron metabolism in bone marrow from adenine-induced mouse model of chronic kidney disease.
Abstract Although the primary cause of anemia in chronic kidney disease (CKD) is lack of sufficient erythropoietin (EPO), other factors may be involved, including the deregulation of iron metabolism. To clarify the mechanism of deranged erythropoiesis in CKD, we evaluated bone marrow (BM) cells in adenine-induced CKD mice. They showed even higher EPO expression in the kidney. Hepatic hepcidin mRNA and plasma hepcidin and ferritin levels were increased. Flow cytometry revealed a decrease in the number of cells expressing transferrin receptor (TfR), or late erythroid progenitors in BM; these cells correspond to proe...
Source: International Journal of Hematology - September 19, 2018 Category: Hematology Authors: Kimura T, Kuragano T, Yamamoto K, Nanami M, Hasuike Y, Nakanishi T Tags: Int J Hematol Source Type: research

Metabolism as master of hematopoietic stem cell fate.
Abstract HSCs have a fate choice when they divide; they can self-renew, producing new HSCs, or produce daughter cells that will mature to become committed cells. Technical challenges, however, have long obscured the mechanics of these choices. Advances in flow-sorting have made possible the purification of HSC populations, but available HSC-enriched fractions still include substantial heterogeneity, and single HSCs have proven extremely difficult to track and observe. Advances in single-cell approaches, however, have led to the identification of a highly purified population of hematopoietic stem cells (HSCs) that ...
Source: International Journal of Hematology - September 15, 2018 Category: Hematology Authors: Ito K, Bonora M, Ito K Tags: Int J Hematol Source Type: research

Systematic review of pre-clinical chronic myeloid leukaemia.
CONCLUSION: This is the first systematic review on pre-clinical CML. This entity requires additional large-scale studies. PMID: 30218276 [PubMed - as supplied by publisher] (Source: International Journal of Hematology)
Source: International Journal of Hematology - September 14, 2018 Category: Hematology Authors: Kuan JW, Su AT, Leong CF, Osato M, Sashida G Tags: Int J Hematol Source Type: research

Tumor long-axis diameter and SUVmax predict long-term responders in 90Y-ibritumomab tiuxetan monotherapy.
Abstract 90Y-ibritumomab tiuxetan (90Y-IT) is widely used, but the factors responsible for its optimal treatment effects are unknown. We enrolled 34 patients with relapsed indolent lymphoma treated with 90Y-IT monotherapy at Gunma University Hospital between 2003 and 2014 in the present study. Clinical data including computed tomography and 18-Fluoro-deoxyglucose positron emission tomography were retrospectively analyzed. The overall response rate and complete response rate were 91% and 82%, respectively. The median progression-free survival (PFS) and overall survival were 32 months and not reached, respectiv...
Source: International Journal of Hematology - September 10, 2018 Category: Hematology Authors: Tsukamoto N, Yokohama A, Higuchi T, Mitsui T, Koiso H, Takizawa M, Shimizu H, Ishizaki T, Matsumoto M, Toyama K, Sakura T, Ogura H, Saitoh T, Ishida F, Murakami H, Tsushima Y, Handa H Tags: Int J Hematol Source Type: research

Concomitant subcutaneous intravascular lymphoma lesions in a patient with cardiac diffuse large B-cell lymphoma: is intravascular lymphoma a distinct clinical entity?
We describe a patient who presented with large cardiac diffuse large B-cell lymphoma (DLBCL) and adrenal masses. The patient also had subcutaneous intravascular lymphoma lesions which were detected by random skin biopsy. Although ambiguous, minimal extravascular location of lymphoma cells is permitted for the diagnosis of intravascular large B-cell lymphoma (IVLBCL) in the WHO definition, a number of rare cases have been reported as having concomitant tumours in other organs, such as the adrenal gland, brain, and penis. We assume that IVLBCL might be a peculiar feature of DLBCL characterised by pre...
Source: International Journal of Hematology - September 8, 2018 Category: Hematology Authors: Abe Y, Usui Y, Narita K, Takeuchi M, Matsue K Tags: Int J Hematol Source Type: research

Safety and efficacy of intravenous ferric carboxymaltose in Japanese patients with iron-deficiency anemia caused by digestive diseases: an open-label, single-arm study.
Abstract Iron-deficiency anemia (IDA) accounts for majority of anemia. Although iron replacement therapy is effective, in Japan, conventional iron formulations have disadvantages such as gastrointestinal side effects for oral formulations and issues of frequent administration for intravenous (IV) formulations. Ferric carboxymaltose (FCM), which overcomes these limitations, is widely used as an IV iron source overseas. In this multi-center, open-label, single-arm study, we investigated the safety and efficacy of FCM up to 12 weeks after the start of administration in patients with IDA caused by digestive diseases. ...
Source: International Journal of Hematology - September 7, 2018 Category: Hematology Authors: Ikuta K, Ito H, Takahashi K, Masaki S, Terauchi M, Suzuki Y Tags: Int J Hematol Source Type: research

Lymphadenopathy with coexisting normal architecture in malignant lymphoma.
PMID: 30191510 [PubMed - as supplied by publisher] (Source: International Journal of Hematology)
Source: International Journal of Hematology - September 6, 2018 Category: Hematology Authors: Saito S, Ogiso Y, Sakashita K Tags: Int J Hematol Source Type: research

Characteristics of methotrexate-induced stroke-like neurotoxicity.
Abstract Intrathecal administration of methotrexate (IT-MTX) can lead to neurotoxicity. MTX-induced neurotoxicity occasionally manifests with a stroke-like presentation that is difficult to distinguish from genuine stroke. We retrospectively reviewed records of nine patients with leukemia or lymphoma and episodes of stroke-like presentation at our institute between 2010 and 2015 for whom magnetic resonance imaging (MRI) data were available. Coagulation test results were compared between the two diagnostic groups. Four patients were diagnosed with MTX-induced stroke-like neurotoxicity. The first neurological event ...
Source: International Journal of Hematology - September 4, 2018 Category: Hematology Authors: Watanabe K, Arakawa Y, Oguma E, Uehara T, Yanagi M, Oyama C, Ikeda Y, Sasaki K, Isobe K, Mori M, Hanada R, Koh K Tags: Int J Hematol Source Type: research

KIF20A, highly expressed in immature hematopoietic cells, supports the growth of HL60 cell line.
Abstract A microtubule-associated motor protein, kinesin-like family member 20A (KIF20A; also called MKlp2) is required for cytokinesis and contributes to intracellular vesicular trafficking. KIF20A plays a critical role in the development of several cancers, but its role in blood cells and hematological malignancies have not been studied. In the present study, we focused on the role of KIF20A in hematopoietic cells and possible involvement in myeloid neoplasms. We found that human leukemia cell lines and normal bone marrow CD34-positive cells stimulated by growth factors, but not mature peripheral blood cells, ex...
Source: International Journal of Hematology - September 4, 2018 Category: Hematology Authors: Morita H, Matsuoka A, Kida JI, Tabata H, Tohyama K, Tohyama Y Tags: Int J Hematol Source Type: research

Correction to: Plerixafor for mobilization and collection of haematopoietic stem cells for autologous transplantation in Japanese patients with non-Hodgkin lymphoma: a randomized phase 2 study.
Abstract The affiliation of the last author, Kenshi Suzuki has been incorrectly published in the original publication of the article. The correct affiliation is provided in this correction. PMID: 30168086 [PubMed - as supplied by publisher] (Source: International Journal of Hematology)
Source: International Journal of Hematology - August 30, 2018 Category: Hematology Authors: Matsue K, Kumagai K, Sugiura I, Ishikawa T, Igarashi T, Sato T, Uchiyama M, Miyamoto T, Ono T, Ueda Y, Kiguchi T, Sunaga Y, Sasaki T, Suzuki K Tags: Int J Hematol Source Type: research

Chronic myeloid leukemia stem cells and molecular target therapies for overcoming resistance and disease persistence.
Abstract Chronic myeloid leukemia (CML) is effectively treated with tyrosine kinase inhibitors (TKI) targeted against BCR-ABL. We previously reported the investigation of residual CML diseases during TKI treatment using FACS-sorting and quantitative RT-PCR of BCR-ABL among each population; total mononuclear cells, hematopoietic stem cells, and myeloid progenitors. The observations also implied that the second-generation of ABL-tyrosine kinase inhibitors (2nd TKIs), dasatinib or nilotinib therapy can be more promising approach for efficient reduction of the CML stem cells. Moreover, we need to develop the evaluatio...
Source: International Journal of Hematology - August 28, 2018 Category: Hematology Authors: Inoue A, Kobayashi CI, Shinohara H, Miyamoto K, Yamauchi N, Yuda J, Akao Y, Minami Y Tags: Int J Hematol Source Type: research

Clinical significance of cancer-related fatigue in multiple myeloma patients.
In conclusion, CRF was one of the major symptoms in MM patients, and predicted shorter OS and PFS in NDMM patients. PMID: 30155589 [PubMed - as supplied by publisher] (Source: International Journal of Hematology)
Source: International Journal of Hematology - August 28, 2018 Category: Hematology Authors: Suzuki K, Kobayashi N, Ogasawara Y, Shimada T, Yahagi Y, Sugiyama K, Takahara S, Saito T, Minami J, Yokoyama H, Kamiyama Y, Katsube A, Kondo K, Yanagisawa H, Aiba K, Yano S Tags: Int J Hematol Source Type: research

Guest editorial: chronic myeloid leukemia.
PMID: 30155590 [PubMed - as supplied by publisher] (Source: International Journal of Hematology)
Source: International Journal of Hematology - August 28, 2018 Category: Hematology Authors: Minami Y Tags: Int J Hematol Source Type: research

Dasatinib-induced anti-leukemia cellular immunity through a novel subset of CD57 positive helper/cytotoxic CD4 T cells in chronic myelogenous leukemia patients.
Abstract Dasatinib induces lymphocytosis of large granular lymphocytes (LGLs) in a proportion of patients with chronic myelogenous leukemia (CML), and is associated with better clinical outcomes. LGLs consist of cytotoxic T lymphocytes and natural killer cells; however, the context and phenotypic/functional features of each type of LGL are unknown. To better define features of these LGLs, we investigated lymphocytosis in CML patients treated with dasatinib. D57-positive and CD4-positive type I T-helper (Th) cells (CD57+ Th cells) rarely occur in CML patients without lymphocytosis and in healthy individuals;...
Source: International Journal of Hematology - August 27, 2018 Category: Hematology Authors: Watanabe N, Takaku T, Takeda K, Shirane S, Toyota T, Koike M, Noguchi M, Hirano T, Fujiwara H, Komatsu N Tags: Int J Hematol Source Type: research

Oncogenic transcriptional program driven by TAL1 in T-cell acute lymphoblastic leukemia.
Abstract TAL1/SCL is a prime example of an oncogenic transcription factor that is abnormally expressed in acute leukemia due to the replacement of regulator elements. This gene has also been recognized as an essential regulator of hematopoiesis. TAL1 expression is strictly regulated in a lineage- and stage-specific manner. Such precise control is crucial for the switching of the transcriptional program. The misexpression of TAL1 in immature thymocytes leads to a widespread series of orchestrated downstream events that affect several different cellular machineries, resulting in a lethal consequence, namely T-cell a...
Source: International Journal of Hematology - August 25, 2018 Category: Hematology Authors: Tan TK, Zhang C, Sanda T Tags: Int J Hematol Source Type: research

KMT2A-rearranged infantile acute myeloid leukemia masquerading as juvenile myelomonocytic leukemia.
Abstract Mixed lineage leukemia [MLL; now known as lysine methyltransferase 2A (KMT2A)] rearrangement-positive acute myeloid leukemia (AML) and juvenile myelomonocytic leukemia (JMML) are distinct diseases, although age of susceptibility (infancy or early childhood) and abnormal monocytosis are common clinical features. Here, we report two cases of KMT2A-rearranged infantile AML masquerading as JMML at initial presentation. Both cases showed leukocytosis accompanied by atypical monocytosis. However, in both cases, leukemic blasts were absent at the initial examination. Thus, a diagnosis of JMML was suspected. Howe...
Source: International Journal of Hematology - August 24, 2018 Category: Hematology Authors: Kanayama T, Imamura T, Kawabe Y, Osone S, Tahara J, Iwasaki F, Miyagawa N, Goto H, Imashuku S, Hosoi H Tags: Int J Hematol Source Type: research

Graft-versus-host disease (GvHD) of the tongue and of the oral cavity: a large retrospective study.
The objective of this study was to identify the impact of GvHD in the oral cavity. We reviewed all consecutive patients who developed oral GvHD after HSCT. The study period was over 14 years. 53 patients were identified. M/F = 1.4; median age was 48.6 years; the median follow-up was for up to 3 years and 6 months. Conditioning regimens included several drugs (e.g., busulfan, cyclophosphamide and fludarabine). In 11 cases, radiotherapy (RT) was also used. Patients treated with RT were more likely to have tooth decay requiring fillings (p = 0.029), to need canal root interventions (...
Source: International Journal of Hematology - August 24, 2018 Category: Hematology Authors: Piccin A, Tagnin M, Vecchiato C, Al-Khaffaf A, Beqiri L, Kaiser C, Agreiter I, Negri G, Kob M, Di Pierro A, Vittadello F, Mazzoleni G, Eisendle K, Fontanella F Tags: Int J Hematol Source Type: research

Three cases of spontaneous splenic rupture in malignant lymphoma.
Abstract Spontaneous splenic rupture is a rare but often life-threatening condition. However, there is no consensus on appropriate management for this condition, due to its rarity. Here, we report three cases of malignant lymphoma with spontaneous splenic rupture. In each case, progression of splenic bleeding was rapid and complicated by malignant lymphoma. Spontaneous splenic rupture complicated by malignant lymphoma may cause exacerbation of anemia and hypovolemic shock. When splenic rupture is indicated by abdominal pain, tachycardia, or hypotension in a patient with splenomegaly, abdominal examination should b...
Source: International Journal of Hematology - August 24, 2018 Category: Hematology Authors: Amaki J, Sekiguchi T, Hiraiwa S, Kajiwara H, Kawai H, Ichiki A, Nakamura N, Ando K Tags: Int J Hematol Source Type: research

A phase 3b, multicenter, open-label extension study of the long-term safety of anagrelide in Japanese adults with essential thrombocythemia.
In conclusion, these results support anagrelide administration to high-risk Japanese ET patients using individualized dosing strategies defined in instructions previously approved in Europe and the USA. PMID: 30121892 [PubMed - as supplied by publisher] (Source: International Journal of Hematology)
Source: International Journal of Hematology - August 18, 2018 Category: Hematology Authors: Kanakura Y, Shirasugi Y, Yamaguchi H, Koike M, Chou T, Okamoto S, Achenbach H, Wu J, Nakaseko C Tags: Int J Hematol Source Type: research

Correction to: Cell dynamics during differentiation therapy with all-trans retinoic acid in acute promyelocytic leukemia.
Abstract In the original publication of the article, Table 2 was published incorrectly. The column names were swapped under the column heading "Prom (%)". The correct column names are PB and BM. PMID: 30101404 [PubMed - as supplied by publisher] (Source: International Journal of Hematology)
Source: International Journal of Hematology - August 12, 2018 Category: Hematology Authors: Sato K, Sakai H, Saiki Y, Uchida A, Uemura Y, Yokoi S, Tsuruoka Y, Nishio Y, Matsunawa M, Suzuki Y, Isobe Y, Kato M, Tomita N, Inoue Y, Miura I Tags: Int J Hematol Source Type: research

Prominent increase of Pappenheimer body-containing erythrocytes in a patient with hypoplastic spleen (IJHM-D-18-00279R2).
PMID: 30083850 [PubMed - as supplied by publisher] (Source: International Journal of Hematology)
Source: International Journal of Hematology - August 6, 2018 Category: Hematology Authors: Inaba T, Ohama A Tags: Int J Hematol Source Type: research

C-terminal RUNX1 mutation in familial platelet disorder with predisposition to myeloid malignancies.
H, Szotkowski T, Mayer J, Pospíšilová Š, Doubek M Abstract Here we report a C-terminal RUNX1 mutation in a family with platelet disorder and predisposition to myeloid malignancies. We identified the mutation c.866delG:p.Gly289Aspfs*22 (NM_001754) (RUNX1 b-isoform NM_001001890; c.785delG:p.Gly262Aspfs*22) using exome sequencing of samples obtained from eight members of a single family. The mutation found in our pedigree is within exon eight and the transactivation domain of RUNX1. One of the affected individuals developed myelodysplastic syndrome (MDS), which progressed to acute myelogen...
Source: International Journal of Hematology - August 6, 2018 Category: Hematology Authors: Staňo Kozubík K, Radová L, Pešová M, Réblová K, Trizuljak J, Plevová K, Fiamoli V, Gumulec J, Urbánková H, Szotkowski T, Mayer J, Pospíšilová Š, Doubek M Tags: Int J Hematol Source Type: research

Advances in gene therapy for hemophilia: basis, current status, and future perspectives.
Abstract Hemophilia is a congenital hemorrhagic disease caused by genetic abnormalities in coagulation factor VIII or factor IX. Current conventional therapy to prevent bleeding requires frequent intravenous injections of coagulation factor concentrates from early childhood. Accordingly, gene therapy for hemophilia remains an exciting future prospect for patients and their families, due to its potential to cure the disease through a one-time treatment. After a series of successes in basic research, recent clinical trials have demonstrated clear efficacy of gene therapy for hemophilia using adeno-associated virus (...
Source: International Journal of Hematology - August 6, 2018 Category: Hematology Authors: Ohmori T Tags: Int J Hematol Source Type: research

Chronic myelogenous leukemia presenting with central nervous system infiltration, successfully treated with central nervous system-directed chemotherapy followed by allogeneic stem cell transplantation.
Abstract With the introduction of tyrosine kinase inhibitors (TKIs), prognosis of chronic myelogenous leukemia (CML) has improved dramatically. However, treatment for blast phase (BP) CML remains a challenge. CML infiltration of the central nervous system (CNS) is particularly rare and no effective treatment strategy has been established. The present case reports a 30-year-old man presenting with sensory deafness. Marked leukocytosis with p210 BCR-ABL1 mRNA positivity and Philadelphia chromosome detected by bone marrow biopsy confirmed the diagnosis of CML. Dura thickening in brain MRI and immature cells with Phil...
Source: International Journal of Hematology - August 4, 2018 Category: Hematology Authors: Chiba A, Toya T, Mizuno H, Tokushige J, Nakamura F, Nakazaki K, Kurokawa M Tags: Int J Hematol Source Type: research